# rvSMR overnight cycle — meta-coordinator final audit

*Date 2026-06-08. Independent cross-team audit of the Team 1 (rvMR implementation + Track 2) / Team 2 (paper-grounded HTML) / Track 5 (pQTL anchor) overnight burst. Auditor read all artifacts on disk; ran tests; ran an independent Type-I simulation. Default to skepticism; flag overclaims.*

## 1. Executive verdict

The overnight burst is **publishable but gap-flagged, NOT Round-4-complete**. Team 1 cleanly converted four of five algorithm stubs from `stop("not implemented")` to mathematically correct, citation-grounded, and locally-tested code; the package goes from 82 → 160 testthat assertions PASS / 0 FAIL with no unauthorized scope creep, and the new code carries an empirically calibrated Type-I rate (independently reproduced at 0.0507 in 3000-rep null simulation, well inside the ±2.5% tolerance Team 1 claimed). Team 2's HTML walkthrough is structurally complete (15 step sections including Step 0; "paper used" sub-badge appears in every step; Step 10 carries the erratum callout), and the cross-team coordination that produced the main.tex Step 10 fix is the genuine win of this cycle — Team 1 surfaced the inconsistency at MS1 (~50% time), Team 2 integrated it, main.tex got fixed in commit `b226793`, and the package is consistent with both. The headline limits are: (1) the Track 2 K=7 → K=2 narrative is a fully honest plumbing test but only K=2 strong instruments survive the Stock-Yogo screen — the "CI excludes 0" claim is the ratio estimate on the two strongest cis-eQTLs, not a rare-variant rvSMR result; (2) Track 5 is honestly reported as degenerate-by-construction (the pQTL anchor cancels per-tissue scale because all 4 included tissues used the same lead variant) and substitutes Pott 2024 for the spec-preferred Sun BB 2023 UKB-PPP; (3) Round-3 Track-1 simulations (AR coverage, Sargan-J, IVW comparator) were NOT re-run, so the headline coverage figure remains at the Round-3 state.

## 2. Status snapshot

| Deliverable | Status | Commit | Evidence quality |
|---|---|---|---|
| 4 stubs + `cell_type_q` impl in rvMR | PASS | `eaaa00a` | High — code on disk; 160/160 tests PASS reproduced locally; math hand-checked against citation_audit |
| `heidi_rv` erratum applied | PASS | `eaaa00a` + `b226793` | High — empirical Type-I 0.0507 in N=3000 null sim; matches Team 1's 0.048 |
| 78 new testthat assertions | PASS | `eaaa00a` | High — `devtools::test()` summary reproduced: annotation_concord 14 / cell_type_concord 16 / heidi_rv 19 / sensitivity 29 dots, 0 fail |
| Track 2 PCSK9→CHD plumbing | PASS (with caveat) | `eaaa00a` | Mid — K=2 result depends on Stock-Yogo screen (pre-specified per VALIDATION_PLAN §4 but inevitably narrative-amplifying); direction matches RCT |
| Team 2 14-step HTML | PASS | `248b57e` | High — 15 sections (Step 0 + Steps 1-14); 15 "paper used" sub-badges; Step 10 erratum callout box present; citations match citation_audit |
| main.tex Step 10 erratum fix | PASS | `b226793` | High — main.tex lines 357 now contains "Erratum (corrected 2026-06-08)" paragraph stating the un-whitened form |
| Track 5 pQTL anchor | PASS (degenerate) | `442a040` | High self-reporting — worker explicitly flags the universal-anchor algebra cancels per-tissue scale; substitution of Pott 2024 for Sun BB 2023 documented with full source log |
| Round-3 Track-1 sim resync | NOT RUN this cycle | (unchanged from `96a1cea`) | N/A — Round-3 VALIDATION_REPORT_v3.md is the authoritative source for coverage tables |

## 3. Check A: Team 1 implementation audit

**4 stubs + 1 new function:**

| Function | File | Math | Tests | Verdict |
|---|---|---|---|---|
| `iv_partial_r2` | `sensitivity.R:48-94` | `R² = t²/(t²+n-2)`, `RV = (√(t²+4)-|t|)/2` (uses `|t|` to keep RV positive for negative b_x — defensible note in implementation comments) | 7 (edge t=0, large t, sign invariance, hand-check, RV_alpha threshold, input validation) | OK |
| `e_value` | `sensitivity.R:143-195` | `RR = exp(0.91·β)`; `E = RR + √(RR(RR−1))` folded over `1/RR` for RR<1; CI-E uses bound nearest null | 7 (hand-check RR=2, symmetric in β sign, CI crosses 0 → E=1, input validation) | OK |
| `annotation_concord` | `annotation_concord.R:85-218` | Per-class delta-method `Var(b_y/b_protein) = SE_y²/b_p² + b_y²·SE_p²/b_p⁴`; Cochran Q with df=K−1 | 7 (concordant→large p, outlier→small p, hand-Q match, delta-method numeric check, K=1 reject, zero anchor reject) | OK |
| `cell_type_q` | `cell_type_concord.R:86-182` (new file) | `Q = Σ w_c (β_c − β̄)²`, w_c = 1/SE², df = C−1, min_donors filter | 7 (concordant, outlier, hand-Q=5 for {1,2,3,4 SE=1}, min_donors filter, post-filter <2 reject) | OK |
| `heidi_rv` | `heidi_rv.R:125-303` | `T = δᵀδ` with Davies weights = nonzero eigenvalues of V_δ (corrected); also reports Mahalanobis `δᵀV⁺δ` + `χ²_{df}` p-value | 8 (concordant→p≈1, outlier→p<0.001, Mahalanobis sister, df_effective check, LD covariance path, 2000-rep null calibration, validation, weights_eig check) | OK |

**160/160 tests verified locally**: I ran `cd /home/francisfenglu4/rvSMR/May_30md/rvMR && Rscript -e 'devtools::test()'`. Output: annotation_concord (14), cell_type_concord (16), heidi_rv (19), mrAR (27), mrAR_multi (48), sensitivity (29), wald_burden (7), all green; ended in `══ DONE ══ Your tests are neat!`. Reproduces Team 1's claim.

**heidi_rv Type-I empirical reproduction (N=3000, m=4, σ=0.10, mean=0)**: empirical Type-I at α=0.05 = **0.0507** (Team 1 reported 0.048 in N=2000; both inside ±2.5%). Mean p-value 0.4985, median 0.4957. Null p-values uniform to a good approximation. The corrected form is genuinely calibrated.

**Unauthorized package changes**: NO. `package_diff.txt` covers only `sensitivity.R`, `annotation_concord.R`, `heidi_rv.R`, `cell_type_concord.R` (new), `NAMESPACE` (+ `mrAR_multi` + `cell_type_q` exports), and four new `tests/testthat/test-*.R` files. `mrAR.R`, `mrAR_multi.R`, `utils.R`, `wald_burden.R` untouched (file mtimes unchanged from May 30 / June 7). Hard constraints respected.

## 4. Check B: Team 2 HTML audit

**14 step sections + Step 0**: confirmed. Sections appear at HTML lines 573 (step0), 636 (step1), 742 (step2), 804 (step3), 900 (step4), 1064 (step5), 1123 (step6), 1188 (step7), 1294 (step8), 1354 (step9), 1417 (step10), 1485 (step11), 1547 (step12), 1605 (step13), 1677 (step14). All 15.

**"用了哪篇 paper 的什么方法" sub-badges**: 15 occurrences (one per step section + Step 0); verified by grep. Complete.

**Citation correctness** (spot-check against `citation_audit_2026-05-27.md` and team2_drafts/citation_audit.md):
- Robins 1994 → *Communications in Statistics — Theory and Methods* 23(8): confirmed at HTML line 1863. PASS.
- Sun KY 2024 *Nature* 631:583 for RGC-ME (NOT Sun BB): confirmed at lines 608, 773, 1865 with an explicit warning gloss "第一作者是 Sun KY, 不是 Sun BB". PASS.
- Cinelli-Hazlett dual cite (2025 PRIMARY *Biometrika* asaf004, 2020 SECONDARY *JRSS-B* 82(1):39): confirmed at lines 1645-1646, 1842-1843. PASS.
- Davies 1980 *Applied Statistics (JRSS Series C)* 29(3):323: confirmed at line 1454, 1846. PASS.
- Han-Eskin 2011 cited only as anti-comparator ("DO NOT cite"): confirmed at lines 1518, 1526, 1537. PASS.
- Sun BB 2024: only appears at line 625 as the ERROR being warned against ("把 RGC-ME 引为 'Sun BB 2024' — 错的, 真正第一作者是 Sun KY"). Correct usage.

**Step 10 erratum callout**: PRESENT at HTML lines 1430-1433. Box explicitly states the inconsistency, simulation Type-I 99% under literal pairing, rvMR uses corrected pairing T=δᵀδ + Davies weights = eig(V_δ) giving 4.8% Type-I. Cross-references "Team 1 验证 2026-06-08". This is the integration win.

**Unresolved pedagogy issues from `pedagogy_review.md`**:
- 7 SVGs recommended, 6 implemented (the missing one is the Step 1 burden aggregation per Team 2's own count). Pedagogy review identified Step 0 DAG and a Step 3 IV DAG as optional-but-helpful; Team 2 includes Step 3 DAG and the pipeline overview. **Net: 1 recommended SVG (Step 1 inline burden picture) deferred**, not blocking.
- All "Chinese phrasing" concerns flagged as "clean" — no rewrite recommended in `pedagogy_review.md`.
- Per `citation_audit.md` "Minor cleanups recommended": Bowden 2015 / Verbanck 2018 / Liu 2019 added to refs list — verified at HTML lines 1818-1851 (citations grouped at the end). PASS.

## 5. Check C: Track 2 reality check

**Selective filtering concern (K=2 strong-IV subset)**: VALIDATION_PLAN.md line 170 explicitly anticipates the Stock-Yogo F>10 screen — *"report coverage two ways — (i) all sub-samples, (ii) only sub-samples where F > 10. The (ii) bar shows what publication bias does to coverage if practitioners screen on Stock–Yogo. rvSMR-AR's argument is precisely 'you don't need to screen'"*. Team 1 reports both: K=7 (ci_type=empty, J p=0.0056, correctly rejects homogeneity) AND K=2 (ci [0.050, 0.124], J p=0.68). The K=2 subset is a pre-specified diagnostic, not post-hoc filtering. **NOT selective reporting in the strict sense.** However: the headline "CI excludes 0, positive sign matches RCT" only holds after the F>10 screen — which is exactly the practitioner-screening behavior the rvSMR-AR paper is supposed to argue *against*. The way this should be written in a paper draft: "K=7 AR-CI is empty (J p=0.006), correctly diagnosing weak-IV-noise pollution; on the strong-IV subset (K=2, F>10) AR gives bounded CI [0.050, 0.124] with J p=0.68". Both lines are needed; reporting only the K=2 line would be the overclaim.

**Direction consistency with evolocumab RCT**: The reasoning in `track2_results.md` line 70-77 is correct. Causal chain: PCSK9 protein UP → more LDLR degradation → reduced hepatic LDL clearance → MORE plasma LDL → MORE atherosclerosis → MORE CHD. Therefore the alt-allele eQTL beta on PCSK9-liver-expression and the alt-allele GWAS beta on CHD should share sign → Wald ratio positive. Team 1's β̂ = +0.074 is positive, consistent with this. Evolocumab/alirocumab RCT direction lowers CHD by lowering PCSK9 *activity* (a downward intervention on the same axis) — Team 1's MR with eQTL up-arrow on expression giving up-arrow on CHD is the **same axis, opposite direction-of-intervention**. The signs are mutually consistent. PASS.

## 6. Check D: Track 5 honesty

**Degenerate-result honesty**: Track 5 is unusually well self-reported. `WORKER_TRACK5_REPORT.md` lines 26-35 and `pcsk9_pqtl_anchor_results.md` lines 51-66 both explicitly state that p collapses from 0.041 → 1.000 because the same outcome variant (rs471705) + same pQTL anchor variant (rs11591147) get used across all 4 tissues, so the tissue index t doesn't appear on the right side of the renormalization. The phrase "algebraically expected outcome of the universal-anchor fallback the spec describes, NOT an independent empirical confirmation" appears verbatim. The internal review (TRACK5_INTERNAL_REVIEW.md) independently recomputes Q-unanchored = 8.27 (matches 8.275) and Q-anchored = 0 (matches 0.0). **This is a NEGATIVE result for the rvSMR Step 11/12 anchor mechanism as run in this substrate** — the test as constructed is non-discriminating because there's no per-variant variation in the anchor. The honest reading is: the pQTL anchor cure is mathematically the right shape but cannot be empirically distinguished from biological homogeneity without a per-tissue lead variant + matched per-variant pQTL anchor, which is not available in public databases for these intergenic eQTL leads.

**Pott 2024 substitute scale**: Sun BB 2023 UKB-PPP was inaccessible (auth-gated everywhere); Pott 2024 *Hum Mol Genet* PMID 38491180 was used (β=0.37189 on log-PCSK9 from 6-cohort meta of LIFE-Heart, LIFE-Adult, LURIC, TwinGene, KORA-F3, GCKD, n≈20 016). `data_pull_log.md` is unusually thorough — 14 source URLs attempted, 12 failed (Synapse auth, AWS 403, Nature Cloudflare, bioRxiv 403, etc.) before settling on the GWAS Catalog REST API. Scale audit in `TRACK5_INTERNAL_REVIEW.md` §(d) explicitly compares Olink NPX vs SomaScan RFU vs ELISA: SomaScan inflates β ~2.4× (Pietzner 2021: 0.883; Gudjonsson 2022: 1.04 vs Pott 0.37); Track 5 correctly does NOT use Pietzner/Gudjonsson. The Pott 2024 mix is partly Olink + partly ELISA across cohorts, comparable in order-of-magnitude to what Sun BB 2023 UKB-PPP would give (NPX scale ~0.4 expected for rs11591147-T at PCSK9). **The renormalization unit "log-OR-CHD per Olink-NPX-comparable unit of plasma PCSK9" is interpretable**; it is NOT "per mg/dL" or "per absolute mass unit". Scale documented honestly; no SomaScan contamination.

## 7. Check E: Cross-team integration

**Team 1 → Team 2 timing**: STATUS_TEAM1.md explicitly logs the erratum at "Milestone 1 / 50%" with the section header "Math choice flagged for cross-team review" and the line *"Team 2: please flag this in your HTML if you reference Step 10."* STATUS_TEAM2.md confirms *"Read Team 1's status at MS1 / 50%: all 5 stubs implemented; 160 tests PASS, 0 FAIL"* and `Updated HTML's "代码位置" subsections at Steps 10, 11, 12, 13, 14: all switched from 🔴 stub to ✅ implemented`. The erratum callout box at HTML line 1430 carries the byline "Team 1 验证 2026-06-08". main.tex commit `b226793` adds an "Erratum (corrected 2026-06-08)" paragraph at line 357 of main.tex. **Timeline verified**: Team 1 surfaced at MS1, Team 2 integrated by MS2, main.tex was patched in a follow-on commit. This is the genuine cross-team win.

**Other cross-team catches**: I scanned for other Team 1 → Team 2 or Team 2 → Team 1 corrections. Found:
1. Team 2's `citation_audit.md` recommended adding Bowden 2015 / Verbanck 2018 / Liu 2019 to the references list (lines 79, 167) — implemented in final HTML.
2. Team 2 spotted that main.tex bibliography lacks Bowden 2015 (Step 14 needs it) — added as comparator reference.
3. Team 1 noted Track 5 backlog (pQTL anchor) in TEAM1_FINAL_REPORT.md line 111, which was then picked up by Track 5 as its specific deliverable. (Cross-track, not cross-team, but related.)

Other than Step 10, **the cross-team catches are all small** — bibliography hygiene rather than substantive math fixes. The Step 10 catch is the single load-bearing example of two-team value.

## 8. Check F: Overclaim register

| Claim | Source | Status | Note |
|---|---|---|---|
| "All 6 deliverables completed" | TEAM1_FINAL_REPORT.md | SUPPORTED | 5 functions + Track 2 all delivered with disk evidence |
| "78 new test assertions, all passing" | TEAM1_FINAL_REPORT.md | SUPPORTED | I reproduced 160/160 locally |
| "Track 2 plumbing test PASSES" | TEAM1_FINAL_REPORT.md | SUPPORTED with caveat | K=7 result is "empty CI + Sargan-J reject" (Team 1 calls this correct rejection); K=2 result is bounded CI excluding 0. Calling the *aggregate* a PASS requires reading both lines. |
| "Direction matches RCT" | TEAM1_FINAL_REPORT.md / track2_results.md | SUPPORTED | Causal-direction reasoning correct; β positive matches the natural direction |
| "Catch & fix of Step 10 math inconsistency" | TEAM1_INTERNAL_REVIEW.md / STATUS_TEAM1.md | SUPPORTED | Erratum is real; main.tex patched in b226793 |
| "HTML 1900 lines, 14 step sections, 19 citation cards" | TEAM2_FINAL_REPORT.md | SUPPORTED (effectively) | 15 sections (Step 0 + 14); "1900 lines" matches; citation cards style verified |
| "All 7 trap items in citation_audit covered correctly" | STATUS_TEAM2.md | SUPPORTED | I spot-checked Robins/Sun KY/Cinelli/Davies/Ray; all correct |
| "Hypothesis confirmed — heterogeneity was scale variation, not biology" | WORKER_TRACK5_REPORT.md (reporting the spec language) | OVERCLAIMED IN SPEC, HONESTLY DOWN-RATED IN BODY | Track 5 own body text repeatedly says "confirmed by construction" / "non-discriminating" — the worker explicitly DOES NOT overclaim. Use the body language, not the spec's quoted line. |
| "pQTL-anchored result collapses Q to 0" | pcsk9_pqtl_anchor_results.md | SUPPORTED | Verified Q=0 by hand re-computation in internal review |
| "Pott 2024 is the closest substitute available on the Olink-compatible log-PCSK9 scale" | data_pull_log.md | SUPPORTED | 14 source URLs attempted; scale audit confirms Olink/SomaScan distinction handled |
| "rvSMR is publishable on the Track-1 simulation axis" | VALIDATION_REPORT_v3.md (pre-existing) | SUPPORTED at Round 3 state | Not re-validated this cycle but unchanged |
| "Round 4 ready" / "Publishable end-to-end" | NOT explicitly claimed by any deliverable | N/A | Implicitly suggested by the overall narrative arc; the explicit verdict is "publishable but gap-flagged" |

The language style across all three deliverables (Team 1, Team 2, Track 5) is **noticeably more conservative than test_run_v3_final/VALIDATION_REPORT_v3.md style** — workers say "PASS" / "OK" / "verified" rather than "proves" / "demonstrates" / "validates". Grep for "validate" returns zero occurrences in TEAM1_FINAL_REPORT.md, TEAM2_FINAL_REPORT.md, WORKER_TRACK5_REPORT.md. The "demonstrates" / "proves" / "validates" overclaim detector did not fire. Honest cycle.

## 9. Check G: Publishable now

| # | Claim | Status | Note |
|---|---|---|---|
| 1 | AR coverage stable 0.94-0.96 across F ∈ [0.25, 60] (Round 3 sim) | SUPPORTED | VALIDATION_REPORT_v3.md §3(a)(b); 21 cells × 3 seeds × 1000 reps; pre-existing |
| 2 | summary-IVW under-covers 4-5 pp at λ < 3 (smaller than Wang-Kang's 25-45 pp due to K=3 vs L=100) | SUPPORTED | VALIDATION_REPORT_v3.md §3(a)(b); rationale for magnitude gap is given |
| 3 | AR over-covers under non-AR confounder DGP (cs sweep) | SUPPORTED | VALIDATION_REPORT_v3.md §3(c); cs ∈ {0.1...1.0} table monotone |
| 4 | Sargan-J detects 1/3-mask invalid pleiotropy at 80.7% (Round 2) | SUPPORTED | pre-existing Round 2 result; needs re-cite in any Round 4 doc |
| 5 | rvMR K=1 mrAR reproduces Wang-Kang 2022 Table 1 BMI→SBP (real data) | SUPPORTED | VALIDATION_REPORT_v3.md §2 (25-SNP β=0.324; 160-SNP β=0.316); pre-existing |
| 6 | rvMR K=1 mrAR on 5 RCT drug-target genes × FinnGen IHD: 5/5 direction match | SUPPORTED | test_run_finngen/ pre-existing; commit 6ae9116 |
| 7 | rvMR K=2 strong-IV subset PCSK9 GTEx Liver × FinnGen CHD: CI [0.050, 0.124], J p=0.68 (Track 2) | SUPPORTED WITH CAVEAT | Real result; must be reported alongside the K=7 empty-CI line. Substrate is bulk Liver not single-cell. |
| 8 | heidi_rv: empirical Type-I ≈ 0.05 after erratum fix | SUPPORTED | I reproduced 0.0507 at N=3000 independently |
| 9 | 160/160 testthat assertions PASS | SUPPORTED | Reproduced locally |
| 10 | cell_type_q across tissues: heterogeneity p=0.041 (unanchored); pQTL anchor result is degenerate | SUPPORTED | Track 5 reports both honestly; the degenerate label is on disk |

All ten claims are publishable as-stated **provided each is reported with the caveats Team 1 / Team 2 / Track 5 already wrote**. The risk is in headline framing: e.g. "rvSMR demonstrates causal PCSK9→CHD" would be an overclaim; "rvSMR's mrAR_multi pipeline runs end-to-end on real GTEx Liver × FinnGen meta data, K=7 panel correctly fails Sargan-J under weak-IV pollution, K=2 strong-IV subset gives RCT-direction-consistent bounded CI" is supported.

Gap items NOT closed by this cycle:
- The Track-1 coverage figure was not re-run with the new code. (Stubs that were filled don't touch mrAR/mrAR_multi math; the figure should still hold but has not been refreshed.)
- The rare-variant exposure data unblock (Wei / Cuomo) is still gated per HANDOVER §6.
- The K-AR analog of the Wang-Kang LD-aware K=25/K=160 reanalysis remains gap (pre-existing).
- Track 5 demonstrated that the universal-anchor fallback is uninformative on the substrate; the "per-tissue lead variant + matched per-variant pQTL anchor" alternative remains untested (needs Sun BB 2023 UKB-PPP auth or a re-pull of eQTL Catalogue at rs11591147 across tissues — flagged by Track 5 itself as the natural follow-up).

## 10. Recommended next steps (ranked)

1. **Re-run Round-3 simulation harness against the now-160-test rvMR to confirm no regression** (the AR/IVW comparator code wasn't touched, but a one-shot sanity sweep against `test_run_v3a/results_v3a.md` would close any "did the new stubs break anything" doubt). 1-2 hr wall time.
2. **Pull eQTL Catalogue effects at rs11591147 across the 9 GTEx tissues used in Track 2 / Track 5** and re-run the pQTL anchor at the canonical pQTL lead variant rather than the universal-anchor fallback. This is the single piece of work that would convert Track 5 from "degenerate by construction" to a real empirical test of the Step-11 cure.
3. **Add a Track 2 paragraph in the paper draft that reports K=7 and K=2 side-by-side** with the explicit note that the K=2 line is illustrative of what Stock-Yogo screening would deliver and is NOT the headline rvSMR result (which is the K=7 J-test correctly flagging the weak-IV pollution). The risk of writing only the K=2 line is real.
4. **Patch the `iv_partial_r2` spec in main.tex Step 13** to match the implementation note about `|t|` vs bare `t` — a small math-consistency erratum analogous to the Step 10 fix. Currently the spec writes `(√(t²+4)-t)/2` which is the form Team 1 had to silently amend to `(√(t²+4)-|t|)/2`. Cleanup, not blocking.
5. **Try Sun BB 2023 UKB-PPP one more time via authenticated Synapse** (requires UKB approval), or contact Wei/Cuomo about TenK10K real-data unblock — both are the canonical-substrate-vs-substitute upgrade for Track 2/3/5.

## 11. Sources cited in this report

All paths verified to exist as of audit time:

- `/home/francisfenglu4/projects/rvSMR_Math/test_run_team1/TEAM1_FINAL_REPORT.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_team1/TEAM1_INTERNAL_REVIEW.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_team1/stubs_implementation.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_team1/track2_results.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_team1/track2_pcsk9.R`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_team1/package_diff.txt`
- `/home/francisfenglu4/rvSMR/May_30md/rvMR/R/sensitivity.R`
- `/home/francisfenglu4/rvSMR/May_30md/rvMR/R/annotation_concord.R`
- `/home/francisfenglu4/rvSMR/May_30md/rvMR/R/cell_type_concord.R`
- `/home/francisfenglu4/rvSMR/May_30md/rvMR/R/heidi_rv.R`
- `/home/francisfenglu4/rvSMR/May_30md/rvMR/tests/testthat/test-sensitivity.R`
- `/home/francisfenglu4/rvSMR/May_30md/rvMR/tests/testthat/test-annotation_concord.R`
- `/home/francisfenglu4/rvSMR/May_30md/rvMR/tests/testthat/test-cell_type_concord.R`
- `/home/francisfenglu4/rvSMR/May_30md/rvMR/tests/testthat/test-heidi_rv.R`
- `/home/francisfenglu4/projects/rvSMR_Math/algorithm_paper_walkthrough.html`
- `/home/francisfenglu4/projects/rvSMR_Math/team2_drafts/TEAM2_FINAL_REPORT.md`
- `/home/francisfenglu4/projects/rvSMR_Math/team2_drafts/citation_audit.md`
- `/home/francisfenglu4/projects/rvSMR_Math/team2_drafts/pedagogy_review.md`
- `/home/francisfenglu4/projects/rvSMR_Math/team_coord/STATUS_TEAM1.md`
- `/home/francisfenglu4/projects/rvSMR_Math/team_coord/STATUS_TEAM2.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_track5/WORKER_TRACK5_REPORT.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_track5/TRACK5_INTERNAL_REVIEW.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_track5/pcsk9_pqtl_anchor_results.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_track5/data_pull_log.md`
- `/home/francisfenglu4/projects/rvSMR_Math/main.tex` (Step 10, lines 337-371)
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_v3_final/VALIDATION_REPORT_v3.md`
- `/home/francisfenglu4/projects/rvSMR_Math/VALIDATION_PLAN.md`
- `/home/francisfenglu4/projects/rvSMR_Math/test_run/CRITIQUE.md` (Round-1 adversarial history)
- `/home/francisfenglu4/projects/rvSMR_Math/test_run_v2/CRITIQUE_v2.md` (Round-2 adversarial history)
- Independent local reproduction: `devtools::test()` output (160 PASS); N=3000 heidi_rv null Type-I = 0.0507.

End of meta-coordinator report.
